Casdin Capital’s Sarepta Therapeutics SRPT Stock Holding History

Casdin Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$3.45M	–	43
2023 Q1	$3.45M	Buy	+25,000	New	+$3.24M	0.28%	36

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Casdin Capital's SRPT Position: Q3 2025 in Review

Casdin Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 990,097 shares — an estimated $16.9M sold.

Casdin Capital first reported a position in SRPT in Q3 2018 and held it in 28 quarters. The position peaked at $170M in Q4 2022. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

Casdin Capital reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
Casdin Capital sold 990,097 Sarepta Therapeutics shares in Q3 2025, an estimated $16.9M.
Casdin Capital first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 28 quarters.
Casdin Capital's Sarepta Therapeutics position peaked at $170M in Q4 2022.
320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.